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http://dx.doi.org/10.1016/j.ccr.2014.05.019SUMMARYPathway-targeted cancer drugs can produce dramatic responses that are invariably limited by the emer-
gence of drug-resistant cells. We found that many drug-treated ‘‘oncogene-addicted’’ cancer cells engage
a positive feedback loop leading to Stat3 activation, consequently promoting cell survival and limiting overall
drug response. This was observed in cancer cells driven by diverse activated kinases, including EGFR, HER2,
ALK, andMET, aswell asmutant KRAS. Specifically, MEK inhibition led to autocrine activation of Stat3 via the
FGF receptor and JAK kinases, and pharmacological inhibition of MEK together with JAK and FGFR
enhanced tumor regression. These findings suggest that inhibition of a Stat3 feedback loop may augment
the response to a broad spectrum of drugs that target pathways of oncogene addiction.INTRODUCTION
Tumors harboring mutationally activated oncogenes are
frequently ‘‘addicted’’ to the consequently activated signaling
pathways (Sharma and Settleman, 2007), rendering them sensi-
tive to drugs that target such pathways (Haber et al., 2011). This
has been observed, for example, in mutationally activated
epidermal growth factor receptor (EGFR)-driven non-small-cell
lung cancers (NSCLCs) treated with EGFR kinase inhibitors,
chronic myelogenous leukemias harboring the BCR-ABL fusion
oncogene upon treatment with ABL kinase inhibitors, BRAF-
mutant melanomas treated with BRAF inhibitors, and EML4-
ALK fusion-containing NSCLCs treated with ALK kinase inhibi-
tors (Haber et al., 2011). However, the relatively rapid emergence
of resistance to these treatments substantially limits the overall
therapeutic benefit, reflecting a nonuniform response to treat-
ment across all tumor cells within a patient and a role for intratu-
mor heterogeneity.
A variety of drug resistance mechanisms have been identified
in diverse cancer models (Holohan et al., 2013). The emergence
of a ‘‘gatekeeper mutation’’ within the kinase domain of the
EGFR, ABL, and ALK kinases is a frequently observed mecha-
nism of drug resistance. Such mutations sterically block theSignificance
Pathway-targeted drug therapies can effectively promote tumo
cally limited in bothmagnitude and duration, prompting the nee
benefit. We have found that pharmacological inhibition of sev
feedback activation of the cell survival protein Stat3, thereby re
ments that disrupt this feedback mechanism led to enhanced c
strategy that may be broadly effective in oncogene-addicted tinteraction of inhibitory drugs with the ATP-binding pocket
(Daub et al., 2004). Other genetic mechanisms of resistance
include activation of compensatory signaling receptors or
effectors by either gene mutation or amplification. For example,
MET amplification,HER2 kinase domainmutations, orPTEN loss
can confer resistance to EGFR-targeted therapy via compensa-
tory survival signaling (Engelman et al., 2007; Wang et al., 2006;
Sos et al., 2009). Additional studies have revealed various ge-
netic mechanisms of resistance to BRAF inhibition, associated
with reactivation of the MAPK pathway due to BRAF amplifica-
tion, NRAS mutation, or MEK mutation (Lito et al., 2013).
Nongenetic mechanisms have also now been widely reported.
Several studies have demonstrated that a subpopulation of
cancer cells can exhibit dependency on an activated pathway
distinct from that which is driving survival of the bulk population
(Bao et al., 2006; Sharma et al., 2010; Roesch et al., 2010). The
role of epithelial-to-mesenchymal transition (EMT) in drug resis-
tance has become increasingly evident, and the link between
EMT and cancer stem cells, which appear to exhibit drug-resis-
tant properties, has become increasingly recognized (Singh and
Settleman, 2010). These apparently nongenetic resistance
mechanisms have been observed in crizotinib-resistant models
of MET-amplified gastric cancer lines and ALK-translocatedr regression in some patients. However, responses are typi-
d for combination treatments to promote longer term clinical
eral pathways of ‘‘oncogene addiction’’ is associated with
ducing the effectiveness of drug treatment. Combining treat-
ell death and delayed resistance, suggesting a cotreatment
umors.
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Additional studies have implicated feedback loops that are
activated following inhibition of PI3K/AKT, BRAF, and MEK/
ERK, associated with upregulation of RTKs, leading to drug
resistance (Chandarlapaty et al., 2011; Prahallad et al., 2012;
Duncan et al., 2012).
Factors secreted from the tumor microenvironment can pro-
mote proliferative or antiapoptotic signaling responses in a vari-
ety of cancer cell contexts (Wilson et al., 2012; Straussman et al.,
2012). Furthermore, production and secretion of factors by can-
cer cells can contribute to intrinsic drug resistance (Yonesaka
et al., 2008). Stressed or dying cancer cells can also release fac-
tors to produce chemoattractant, anti-inflammatory, and proin-
flammatory signals (Krysko and Vandenabeele, 2008; Huang
et al., 2011). In light of the increasingly appreciated heteroge-
neous response to drug treatment in a cancer cell population,
we set out to determine whether drug-sensitive oncogene-
addicted cancer cells secrete factors, upon drug treatment,
that contribute to drug resistance via feedback mechanisms.
RESULTS
EGFR Inhibition Activates Stat3 Signaling in EGFR-
Mutant Lung Cancer Cells
We investigated the possibility that factors secreted from drug-
treated cancer cells could contribute to drug resistance of
neighboring cells that had not experienced drug exposure. We
used PC-9 NSCLC cells, which harbor an activating EGFR
mutation and are sensitive to the EGFR tyrosine kinase inhibitors
(TKIs) erlotinib and gefitinib (Sharma et al., 2007). We first tested
whether conditioned media (CM) from erlotinib-treated PC-9
cells affects erlotinib sensitivity in naive PC-9 cells. Preincuba-
tion of PC-9 cells with erlotinib-treated CM (erlotinib-CM) signif-
icantly increased the number of erlotinib-resistant cells (Figures
1A–1C). To extend this finding in a coculture context, we estab-
lished a fluorescence-based colony formation assay. We used
PC-9 cells that stably express GFP and maintain comparable
erlotinib sensitivity to parental PC-9 (PC-9/GFP) cells (Figure S1A
available online). Parental PC-9 cells were incubated with
DMSO-CM, and PC-9/GFP cells were incubated with erlotinib-
CM. Cells were then cocultured at either 1:1 or 2:1 cell number
ratios. Erlotinib was added the next day, and resistant colonies
were quantified after 5 weeks. The number of GFP-positive col-
onies from erlotinib-CM-treated cells was 4-fold higher in the 1:1
mixture condition and 2-fold higher in the 2:1 mixture condition
than DMSO-CM treated groups, consistent with a role for
secreted factors in erlotinib-CM in promoting drug resistance
(Figures 1D and 1E).
To identify the relevant secreted factors, we undertook two
approaches. First, using antibody arrays that detect 500
secreted growth factors and cytokines, we identified 19 proteins
significantly increased by erlotinib (Figures S1B and S1C). Sec-
ond, to examine signaling pathways affected by erlotinib-CM
or erlotinib itself, we evaluated 45 cancer-related signaling path-
ways that affect gene expression using a reporter array. Both
erlotinib-CM (3 hr) treatment and erlotinib (24 hr) treatment
effectively increased transcriptional activities of stress/immune
response-associated factors, such as Stat3, IRF-1, interferon208 Cancer Cell 26, 207–221, August 11, 2014 ª2014 Elsevier Inc.gamma, or type I interferon, and pax6, which is involved in
stem cell and differentiation signaling (Figure 1F; Figure S1D).
However, short erlotinib treatment (3 hr) did not cause any signif-
icant changes (data not shown), suggesting that these signaling
responses are not activated immediately downstream of EGFR
but are probably engaged through feedback activation.
Several of the factors identified by antibody arrays, such as
interleukin-6 (IL-6), interleukin-1a (IL-1a), and galectin, can acti-
vate Stat3, and reporter activities of Stat3 and IRF-1, a direct
target of Stat3, were dramatically increased by erlotinib (Yu
et al., 2009), highlighting a likely role for Stat3 signaling in feed-
back regulation of drug resistance. We therefore determined
whether erlotinib-CM from PC-9 cells can activate Stat3 through
autocrine or paracrine signals in several other EGFR-mutant
NSCLC lines. As expected, PC-9 erlotinib-CM increased Stat3
phosphorylation at Y705 in PC-9 cells as well as in other erloti-
nib-sensitive EGFR-mutant cell lines (Figure 1G). Treatment
with erlotinib-CM collected at several time points following erlo-
tinib exposure demonstrated that pStat3 was detected at 36 hr
and gradually increased with time, suggesting that Stat3 is
engaged by secreted factors that accumulate during drug treat-
ment (Figure S1E). Significantly, erlotinib directly increased
pStat3 in all tested lung cancer cell lines that express activating
EGFR mutants, except HCC827 cells, but did not affect pStat3
in EGFR wild-type cells (Figure 1H). pStat3 was selectively acti-
vated among other Stat family members (Figure S1F). These
findings suggest that specific feedback activation of Stat3 is
frequently observed upon erlotinib treatment in the context of
EGFR addiction.
Stat3 Activation Promotes Erlotinib Resistance
We next examined whether Stat3 activation affects the overall
erlotinib response in EGFR-addicted cells. Stat3 depletion by
RNAi in four different EGFR-mutant cell lines that showed signif-
icant Stat3 activation following erlotinib dramatically acceleraed
apoptosis induction by erlotinib (Figures 1H and 2A). Consistent
with the lack of Stat3 feedback in the HCC827 cell line, Stat3
knockdown had no such effect on apoptosis in these cells in
response to erlotinib (Figure 2A). Stat3 RNAi also reduced overall
cell viability in erlotinib-treated PC-9 cells (Figure 2B).
To further explore the role of Stat3 in a long-term drug treat-
ment associated with acquired drug resistance, we introduced
Stat3 small interfering RNA (siRNA) followed by 4 weeks of
erlotinib treatment. Transient Stat3 knockdown was sufficient
to suppress erlotinib-resistant colony formation in PC-9 and
HCC4006 cells (Figures 2C and 2D), suggesting that early feed-
back activation of Stat3 contributes to the emergence of drug
resistance. To confirm this observation, PC-9 cells expressing
inducible Stat3 small hairpin RNAi were generated and tested
in the colony formation assay (Figures 2E and 2F). Inducible
Stat3 knockdown efficiently prevented erlotinib-resistant PC-9
colonies (Figure 2G).
Stat3 is activated by homo- or heterodimerization with other
Stat family members via Src homology 2 domains of one mono-
mer and the phospho-Y705 residue of the other (Shuai et al.,
1994; Wen et al., 1995). Substitution of amino acids 662 and
664 to cysteines promotes Stat3 dimerization and constitutive
activation (Bromberg et al., 1999). We generated PC-9 cells
that stably express wild-type and constitutively active Stat3
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Figure 1. Erlotinib Activates Stat3 Signaling in EGFR Mutant Lung Cancer Cells
(A) PC-9 cells were treatedwith DMSO or erlotinib (Erl, 1 mM) for 72 hr. CM (DMSO-CMor erlotinib-CM)was collected and incubated with fresh PC-9 cells for 15 hr
followed by further erlotinib treatment for 28 days. Established erlotinib-resistant colonies after drug treatment were stained with sapphire 700.
(B) Drug-tolerant cells, treated as in (A), were counted on days 3, 6, and 9, and fold changes are shown relative to control-treated cells. Error bars represent
mean ± SEM.
(C) Established erlotinib-resistant colonies fromAwere counted after 28 days of drug treatment, and fold changes are shown relative to control-treated cells. Error
bars represent mean ± SEM.
(D) PC-9 cells preincubated with CM fromDMSO-treated cells, and PC-9/GFP cells preincubated with CM from erlotinib-treated cells weremixed at 1:1 or 2:1 cell
number ratios. After 24 hr, erlotinib was added and maintained for 28 days. Erlotinib-resistant colonies were visualized by sapphire 700 or immunostaining with
anti-GFP antibody.
(E) Fold changes to control drug-resistant colonies was measured as in (A). Error bars represent mean ± SEM.
(F) PC-9 cells were reverse-transfected with luciferase reporters of 45 transcription factors for 48 hr. CM from erlotinib- or DMSO-treated PC-9 cells was
incubated with cells for 3 hr and 45 transcription factors activities were assessed using the Cignal 45 assay. Log2 fold change was assessed by dividing the
luciferase activities of erlotinib-CM treated samples by those of DMSO-CM treated samples. Error bars represent mean ± SEM.
(G) CM from PC-9 cells treated with DMSO (DM) or erlotinib (Erl) was incubated with the indicated EGFR-mutant lung cancer cell lines for 3 hr. Phosphorylated
(pStat3 Y705) and total (T) Stat3 levels were determined by western blot. GAPDH served as a loading control. PC-9.C1 is a PC-9-derived clone with reduced
erlotinib sensitivity.
(H) EGFR-mutant or wild-type lung cancer cell lines were treated with or without erlotinib (1 mM) for 24 hr. pStat3 and T-Stat3 levels were determined by western
blot. GAPDH serves as a loading control.
All erlotinib-resistant colony formation assays were performed in 10-cm dishes, and representative entire dishes are shown. See also Figure S1.
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Drug Resistance via Feedback Activation of Stat3(Stat3-CA) to further examine the role of Stat3 in drug resistance.
Stat3-CA is constitutively phosphorylated at Y705 and localized
in the nucleus (Figure 2H; Figure S2). As expected, Stat3-CA
induced a significant erlotinib half maximal inhibitory conce-
ntration (IC50) shift in a 3-day viability assay and dramaticallyincreased erlotinib-resistant colonies (Figures 2I and 2J).
Notably, Stat3-CA is further phosphorylated following erlotinib
(Figure 2H), suggesting that Stat-CA is not fully active,
which may explain why not all cells expressing Stat3-CA sur-
vived and became resistant to erlotinib (Figures 2I and 2J).Cancer Cell 26, 207–221, August 11, 2014 ª2014 Elsevier Inc. 209
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Figure 2. Stat3 Feedback Activation Mediates Erlotinib Resistance
(A) Cells were transfected with either nontargeting control (NTC) siRNA or Stat3 siRNAs for 48 hr followed by erlotinib (1 mM) treatment for 24 hr. Stat3 knockdown
efficiency and erlotinib efficacy were measured by suppression of pStat3, and pEGFR levels (corresponding total [T-] protein levels also shown). Cleaved PARP
(c-PARP) indicates apoptosis. GAPDH serves as loading control.
(B) Cell viability was measured by Cell Titer-Glo of cells treated as in (A), but for 48 hr. Error bars represent mean ± SEM.
(C) Cells were transfected with either NTC siRNA or Stat3 siRNAs for 48 hr followed by DMSO for 6 days or erlotinib (1 mM) for 4 weeks. The remaining cells were
stained as in Figure 1A.
(D) The number of erlotinib-resistant colonies formed from (C) was quantified. Error bars represent mean ± SEM.
(E) Doxycycline-inducible shStat3-expressing cells were established from PC-9 cells. Stat3 expression was detected by western blot. GAPDH is used as a
loading control.
(legend continued on next page)
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Drug Resistance via Feedback Activation of Stat3Collectively, these findings support a role for feedback activation
of Stat3 following erlotinib treatment in limiting the overall drug
response of a population of EGFR-addicted NSCLC cells.
Stat3 Is Activated through IL-6/JAK1 and FGFR/PI3K
Signaling Pathways
To further explore the mechanism of Stat3 feedback activation,
we examined global gene expression changes in four EGFR-
mutant cell lines upon erlotinib treatment. We found significant
gene expression changes in all of these cells, but not in EGFR
wild-type cells (Figure S3). We focused on transcriptional
changes associated with secreted proteins and identified 444
genes significantly changed by erlotinib treatment (Figure 3A).
To identify candidate upstream activators of Stat3 signaling,
243 genes consistently upregulated by erlotinib were analyzed
using Ingenuity Pathway Analysis (IPA; Qiagen). IPA revealed
a direct connection between FGFR2/3 and Stat3 (Figure 3B).
Notably, expression of multiple genes associated with FGFR
signaling pathways, including FGFR2, FGFR3, FRS2, FGF13,
and HSPG2, was also significantly increased by erlotinib
(Figure 3A).
In addition to changes in gene expression, posttranslational
regulation of secreted factors can contribute to the level of
secretion and strength of signal transduction through receptors.
For example, several Stat3-associated factors whose secretion
was increased in the soluble factor arrays were not changed in
expression level, including FGF16 and IL-6 (Figures S1B and
S1C). In addition to FGFR signaling, we focused on cytokine
secretion, because cytokines, including interleukins, are Stat3
activators. Notably, we observed only a 2-fold increase in IL-6
secretion following erlotinib, among 23 cytokines examined (Fig-
ure 3C). However, when considered in the context of the protein
array results (Figure S1C), a 6-fold increase in IL-1a secretion
and 2-fold increase in IL-6 may be sufficient to trigger IL-6/
JAK/Stat signaling.
To verify a role for FGFR and IL-6/JAK signaling in feedback
Stat3 activation, PC-9 cells were cotreated with erlotinib and in-
hibitors of FGFRs (PD173074) and JAKs (ruxolitinib). FGFR or
JAK inhibitor treatment partially blocked the erlotinib-induced
pStat3 increase, while combining both inhibitors completely
suppressed pStat3 induction (Figure 3D). We then targeted
each JAK family member using RNAi in the context of the IL-6/
Stat3 signaling axis. JAK1 knockdown selectively blocked
pStat3 (Figure 3E). Because PI3K is a common downstream
mediator of RTKs, we examined the potential role of PI3K in
mediating the effect of FGFR on pStat3. Using PI3K inhibitors,
we found that PI3Ka and PI3Kb are required for Stat3 activation
(Figure 3F). Additionally, we detected increased physical interac-
tion between JAK or FGFR and Stat3 following erlotinib, further(F) Three independent clones were treated with DMSO for 6 days or erlotinib (1
formation. The remaining cells were stained as in Figure 1A.
(G) The fraction of control for erlotinib-resistant colonies formed from (F) was qu
(H) Generation of PC-9 cells stably expressing GFP, wild-type Stat3, or constitutiv
GAPDH served as a loading control.
(I) Cells were treated with erlotinib for 72 hr to measure viability by Cell Titer-Glo
(J) Cells were treated with DMSO for 6 days or erlotinib (1 mM) for 4 weeks to me
Figure 1A.
All cell staining was performed in 10-cm dishes and entire dishes are shown. Seconfirming that these two pathways function together to pro-
mote Stat3 activation (Figure 3G). Together, these findings
indicate that FGFR and IL-6 signaling coordinately activate
Stat3 upon erlotinib treatment.
RTK/MEK Inhibition Activates Stat3 in Diverse
Oncogene-Addicted Cancer Models
To examine the possibility that Stat3 is activated in response
to other apoptosis-promoting drugs, PC-9 cells were treated
with EGFR TKIs, DNA-damaging agents, or antimitotic agents,
all of which efficiently induced apoptosis (Figure 4A). Notably,
only EGFR TKIs or EGFR knockdown by siRNA increased
pStat3, indicating that Stat3 activation is specific for EGFR inhi-
bition in these EGFR-addicted cells, regardless of the induction
of apoptosis (Figure 4A; Figure S4A).
Two of the major signaling pathways activated by RTKs,
including EGFR, are the PI3K/AKT and RAS/MEK/ERK pathways
(Sharma et al., 2007). To determine whether these pathways
mediate feedback activation of Stat3, we treated four EGFR-
mutant NSCLC lines with erlotinib, a PI3K inhibitor (GDC0941),
or a MEK inhibitor (AZD6244) and examined pStat3. AZD6244
promoted pStat3 to a similar degree as erlotinib, while
GDC0941 actually slightly suppressed pStat3 in some cell lines
(Figure 4B). A time course study showed that AZD6244 pro-
moted pStat3 as early as 3 hr after treatment (Figure S4B). To
extend this observation, we used immortalized murine NR6
fibroblasts stably expressing an activating EGFR mutant (Lee
et al., 2013). Erlotinib or AZD6244 efficiently inhibited EGFR-
driven pERK activation, leading to increased pStat3 and con-
firming that feedback activation of Stat3 is directly mediated
by EGFR/MEK inhibition (Figure S4C).
We extended these findings to investigate MEK inhibition-
mediated Stat3 activation in other cancer models. First, we
looked at lung cancer lines that harbor wild-type EGFR and do
not exhibit increased pStat3 following erlotinib (Figure 1H). In
these cells, pStat3 was increased by AZD6244 in a time-depen-
dent manner, indicating that MEK is not driven by EGFR in
these cells and that Stat3 activation following MEK inhibition is
observed independently of EGFR activity (Figure S4D). Because
MEK is regulated by RTKs in most RTK-driven cancers, we then
examined a potentially broader role for Stat3 feedback in other
RTK-addicted cancer cell lines. Cancer cells addicted to
HER2, ALK, and MET kinases demonstrated substantial pStat3
increase following treatment with an RTK-targeted drug or a
MEK inhibitor. Notably, pStat3 was transiently decreased at
early time points and then restored at later time points by ALK
or MET inhibitors in KELLY, SH-SY5Y, and three MET-amplified
cancer lines. In contrast, MEK inhibition did not affect pStat3 at
6 hr but increased pStat3 at 24 hr after treatment, implicatingmM) for 4 weeks with or without doxycycline to assess drug-resistant colony
antified. Error bars represent mean ± SEM.
ely active Stat3. pStat3 and T-Stat3 expression were detected by western blot.
. Error bars represent mean ± SEM.
asure drug-resistant colony formation. The remaining cells were stained as in
e also Figure S2.
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Figure 3. Feedback Activation of Stat3 through FGFR and IL-6 Signaling
(A) EGFRwild-type or EGFR-mutant lung cancer cell lines were treated with erlotinib (1 mM) for 24 hr, and mRNA was analyzed by microarray. Upregulated genes
in the FGFR/Stat3 signaling pathway are indicated among significantly changed genes associated with secreted proteins.
(B) IPA using microarray data.
(C) PC-9 cells were treated either with DMSO or erlotinib (1 mM) for 72 hr. Supernatants were collected, and cytokine secretion of the indicated cytokine was
determined by the Luminex cytokine assay. Error bars represent mean ± SEM.
(D) PC-9 cells were treated with erlotinib (1 mM) alone or in combination with PD173074 (2 mM) and ruxolitinib (0.5 mM) for 24 hr. Effects on levels of pStat3 relative
to T-Stat3 were detected by western blot. b-Actin served as a loading control.
(E) siRNAs specific for each JAK family member were transfected into PC-9 cells for 48 hr. After erlotinib (1 mM) treatment for 24 hr, cells were analyzed bywestern
blot for levels of the indicated proteins. GAPDH served as a loading control.
(F) PC-9 cells were treated with various concentrations of isoform-specific PI3K inhibitors and erlotinib (1 mM) for 24 hr. pStat3 and T-Stat3 were detected by
western blot. GAPDH served as a loading control.
(G) PC-9 cells were treated with DMSO or erlotinib (1 mM) for 24 hr. Cells were then lysed and control anti-immunoglobulin G (IgG) or anti-Stat3 antibody was used
for coimmunoprecipitation. Physical interaction between Stat3, FGFR3, and JAK1 was determined by western blot.
See also Figure S3.
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pStat3 expression changes upon RTK or MEK inhibition
Cancer cell
lines Drivers
Targeted
Drugs
pStat3 fold
increase by RTK
inhibition
pStat3 fold
increase by MEK
inhibition
PC-9 EGFR Erlotinib 3.56 4.11
HCC4006 EGFR Erlotinib 3.91 7.19
HCC2279 EGFR Erlotinib 2.67 5.09
HCC2935 EGFR Erlotinib 3.79 5.16
AU565 Her2 Lapatinib 4.89 2.91
BT474 Her2 Lapatinib 2.49 2.42
SKBR3 Her2 Lapatinib 7.03 3.14
H2228 ALK TAE684 0.18 0.48
KELLY ALK TAE684 6.44 (Reactivation) 1.23
SH-SY5Y ALK TAE684 1.47 (Reactivation) 2.05
EBC-1 Met Crizotinib 14.21 (Reactivation) 2.35
KATO II Met Crizotinib 4.54 (Reactivation) 1.02
GTL16 Met Crizotinib 7.28 (Reactivation) 0.95
Figure 4. RTK/MEK Inhibition Activates Stat3 in Diverse Oncogene-Addicted Cancer Models
(A) PC-9 cells were treated with EGFR inhibitors (erlotinib 1 mM, afatinib 1 mM), DNA-damaging agents (cisplatin 40 mM, etoposide 40 mM, doxorubicin 20 mM), or
antimitotic agents (docetaxel 100 nM, paclitaxel 10 mM) for 24 hr. pStat3, T-Stat3, and c-PARP were detected by western blot. GAPDH served as a loading
control. c-PARP indicates apoptosis.
(B) EGFR-mutant cell lines were treated with erlotinib, GDC0941 (2 mM), or AZD6244 (5 mM) for 24 hr. pEGFR, pStat3, pAKT, and pERK were detected by western
blot. GAPDH served as a loading control.
(C) Summary table corresponding to pStat3 level changes upon RTK or MEK inhibition shown in Figure S4E. Fold changes in pStat3 levels were measured by
densitometry.
(D) Stat3 siRNAs were transfected into the various indicated cell line models for 48 hr, followed by treatment with lapatinib (2 mM), crizotinib (1 mM), or TAE684
(1 mM) for 24 hr. Stat3 expression was detected by western blot. b-Actin served as a loading control. c-PARP was measured as an apoptosis marker, and fold
changes were measured by densitometry in the presence of inhibitors.
See also Figure S4.
Cancer Cell
Drug Resistance via Feedback Activation of Stat3MEK inhibition as the major driver of Stat3 activation (Figure 4C;
Figure S4E). Significantly, cotreatment with RTK inhibitors and
Stat3 siRNA enhanced apoptosis in three of five tested cell lines:
SKBR3, EBC-1, and KELLY cells (Figure 4D). These findings
suggest that feedback activation of Stat3 is commonly engaged
by drug treatment in diverse RTK-addicted cancer cells and con-
tributes significantly to the overall response to drug.
Cotargeting of JAK and FGFR Suppresses Stat3
Feedback Signaling and Drug Resistance
We next determined whether Stat3 inhibitors could block erloti-
nib-induced Stat3 activation and thereby sensitize EGFR-ad-
dicted cancer cells to erlotinib. We tested three different Stat3
inhibitors (stattic, SD1008, and cucurbitacin I) that function
through distinct inhibitory mechanisms. Stattic, which targets
the Stat3 SH2 domain and prevents dimerization, did not affect
pStat3 induction, whereas SD1008, a JAK2/Stat3 inhibitor, andcucurbitacin I, which inhibits JAK2 or blocks DNA binding of
constitutively active Stat3, potently suppressed pStat3 induction
by erlotinib (Wang et al., 2012) (data not shown; Figure S5A).
However, further evaluation of cucurbitacin I revealed significant
single-agent cytotoxicity, reducing the likely utility of this agent
for combination treatment (Figure S5B).
Because FGFR and JAK1 coordinately mediate erlotinib-
induced pStat3, we examined whether cotargeting of FGFR
and JAK1 in combination with erlotinib could disrupt erlotinib
resistance. In a search for potentially relevant clinically utilized
multikinase inhibitors, we focused on ponatinib, which targets
all four FGFRs and JAK1 in vitro and has been in clinical
development for the treatment of FGFR mutant lung cancer
(O’Hare et al., 2009). PC-9 cells were treated with erlotinib,
AZD6244, or ponatinib alone or in combination. Ponatinib
alone suppressed pStat3 (Y705) as efficiently as the combination
of PD173074 and ruxolitinib in the presence of erlotinib orCancer Cell 26, 207–221, August 11, 2014 ª2014 Elsevier Inc. 213
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Drug Resistance via Feedback Activation of Stat3AZD6244, suggesting that ponatinib potently inhibits FGFRs and
JAK1 in PC-9 cells (Figure 5A). To determine whether ponatinib
affects cell viability in combination with erlotinib, we performed
a three-day cell viability assay. Although ponatinib alone did
not affect cell viability (Figure S5C), cotreatment with erlotinib
significantly shifted the IC50 and 90% inhibitory concentration
in both PC-9 and HCC4006 cells. Moreover, ponatinib dramati-
cally reduced acquired resistance to erlotinib (Figures 5B and
5C). Ponatinib showed similar efficacy in HCC2279 cells (Fig-
ures S5D and S5E).
To extend these findings to HER2-, MET-, and ALK-driven
cancer models, we assessed the short- or long-term efficacy
of ponatinib in combination with RTK inhibitors. Ponatinib alone
was ineffective in all cell lines tested but synergistically sensi-
tized cells to lapatinib (HER2 inhibitor), crizotinib (MET inhibitor),
and TAE684 (ALK inhibitor), respectively. Moreover, ponatinib
prevented feedback activation of Stat3 following RTK inhibition
and increased apoptosis. Notably, ponatinib alone inhibited
basal pStat3 without affecting pAKT in EBC-1 and KELLY cells,
suggesting that PI3K/AKT and Stat3 signaling may function in
parallel, downstream of MET or ALK, but that only Stat3 can
be reactivated in the presence of RTK inhibitors (Figure 5D).
Consistently, ponatinib significantly prevented drug-resistant
colonies when combined with each RTK inhibitor (Figures 5E
and 5F). These findings indicate that cotargeting FGFRs and
JAK disrupts a RTK inhibitor-driven Stat3 feedback activation
loop that contributes to drug resistance in a variety of RTK-
dependent cancer cells.
Feedback Activation of Stat3 Mediates Resistance to
MEK Inhibition in KRAS Mutant Lung Cancers
We had noted that H23 and H838 NSCLC cells, which showed a
significant pStat3 increase following MEK inhibition, harbor a
KRAS mutation (Figure S4D). Significantly, AZD6244 induced
Stat3 activation in KRAS G12D-overexpressing 293 cells, and
ponatinib disrupted this feedback loop, further implicating
MEK inhibition in triggering Stat3 feedback through FGFRs and
JAK1 in KRAS mutant-driven cancers (Figure S6A). Therefore,
we examined Stat3 feedback in KRAS-driven cancers. We
treated eight KRAS mutant lung cancer lines and ten KRAS
mutant colon cancer cell lines with AZD6244 and measured
pStat3. All eight lung cancer lines exhibited pStat3 increase,
whereas only one wild-type KRAS lung and one KRAS mutant
colon cell line showed a slight increase upon MEK inhibition.
Notably, most lines demonstrating Stat3 feedback express
elevated total Stat3, suggesting that cells with abundant Stat3
are more likely to engage the Stat3 feedback loop (Figure 6A).
Significantly, Stat3-directed RNAi in the presence of MEK
inhibition demonstrated a role for Stat3 feedback activation in
resistance to MEK inhibition in several of the KRAS mutant
lung cancer cell lines (Figure 6B).
We then determined whether FGFR and JAK are similarly
involved in Stat3 feedback activation in KRAS mutant cells. In
H2009, H2030, and H2122 cell lines, pStat3 was partially sup-
pressed either by PD173074 or ruxolitinib and fully suppressed
by the PD173074/ruxolitinib combination. PARP cleavage was
closely correlated with pStat3 suppression, suggesting that
Stat3 signaling antagonizes MEK inhibitor-mediated apoptosis
(Figure 6C; Figure S6B). Ponatinib, combined with AZD6244,214 Cancer Cell 26, 207–221, August 11, 2014 ª2014 Elsevier Inc.completely suppressed pStat3 in H2009 and H2030 cells.
Although ponatinib was slightly less efficient in inhibiting pStat3
than the PD173074 and ruxolitinib combination in H2122 cells
(Figure 6C), combining ponatinib with AZD6244 effectively pre-
vented AZD6244 resistance, confirming that Stat3 activation
through FGFR and JAK contributes to drug resistance in KRAS
mutant lung cancer cells (Figures 6D–6F).
Ponatinib and Ruxolitinib Enhance Regression of
Oncogene-Addicted Tumors
To extend these in vitro findings, we performed xenograft studies
in cell-line models of EGFR and KRASmutant NSCLCs. We first
verified the ability of ponatinib to suppress pStat3 upon erlotinib
treatment in PC-9 xenografts. We detected significantly
increased pStat3 about 48 hr after initial dosing of erlotinib,
consistent with the observation in vitro. Notably, the basal pStat3
level in PC-9 tumors was significantly higher than was observed
in vitro. Despite elevated basal Stat3, we could detect partial
suppression of pStat3with ponatinib, and the combination of po-
natinib and ruxolitinib very effectively suppressed pStat3 (Fig-
ure 7A), possibly implicating additional JAK family members in
Stat3 signaling in vivo.
For an efficacy study, we used HCC4006 cells, because PC-9-
derived tumors were associated with severe ulceration about
14 days after the inoculation. HCC4006 xenografts were treated
with vehicle, ponatinib, erlotinib, or ruxolitinib individually and in
various combinations for 18 days when the tumor sizes of the
vehicle group reached 1,200 mm3. The erlotinib/ruxolitinib com-
bination more effectively retarded tumor growth compared with
erlotinib-only treated tumors. Interestingly, both erlotinib/ponati-
nib and erlotinib/ponatinib/ruxolitinib combinations strongly
induced tumor regression, suggesting that FGFR/Stat3 signaling
may play a more important role in EGFR TKI resistance in the
EGFR-mutant NSCLC model (Figure 7B).
To examine ponatinib efficacy in aKRASmutant model in vivo,
we tested H2122 cells. When tumors reached 300 mm3, vehicle,
GDC0973 (MEK inhibitor), ponatinib, or ruxolitinib was orally
administrated. Although pStat3 was not completely suppressed
by ponatinib, pStat3 was significantly decreased either by pona-
tinib or ruxolitinib (Figure 6C) and was completely suppressed by
the combination of ponatinib and ruxolitinib (Figure 7C). Further
dosing led to dramatic tumor regression in groups treated with
both GDC0973/ponatinib and GDC0973/ruxolitinib/ponatinib.
Notably, the GDC0973/ruxolitinib combination caused signifi-
cant tumor growth inhibition relative to GDC0973 single-agent
treatment. This suggests that both FGFR-Stat3 and JAK-Stat3
signaling pathways are required for mutant KRAS lung tumor
growth in the presence of a MEK inhibitor in vivo (Figure 7D).
GDC0973/ruxolitinib/ponatinib treatment caused a maximum
10% to 15% body weight loss (Figure S7A). These findings
confirm the in vitro observations supporting the role of a
FGFR/JAK-Stat3 feedback activation loop that limits the overall
response to drug treatment of oncogene-addicted tumors.
Stat3 Feedback Activation Is Associated with Poor
Prognosis in Lung Adenocarcinoma
To investigate the transcriptional response to Stat3 feedback
activation, we identified chromatin-binding sites for activated
Stat3 by ChIP-Seq with a pStat3 antibody in PC-9 cells. pStat3
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Figure 5. Cotargeting of JAK and FGFRs Efficiently Inhibits Stat3 Feedback and Resistance to RTK Inhibitors
(A) PC-9 cells were treated with erlotinib (1 mM) or AZD6244 (5 mM) alone or in combination with PD173074 (2 mM), ruxolitinib (0.5 mM), or ponatinib (2 mM) for 24 hr.
Effects on levels of pStat3 relative to T-Stat3 were detected by western blot. b-Actin served as a loading control.
(B) Cell viability of PC-9 cells was measured by Cell Titer-Glo following erlotinib or ponatinib (1 mM) alone or in combination for 72 hr. For the colony formation
assay, cells were treated with DMSO or ponatinib for 6 days or erlotinib with or without ponatinib for 28 days. The remaining cells were stained by crystal violet,
and the fraction of control for drug-resistant colonies after 28 days was measured by densitometry. Error bars represent mean ± SEM.
(C) HCC4006 cells treated as in (B). Error bars represent mean ± SEM.
(D) Cell viability of SKBR3, EBC-1, or KELLY cells was measured by Cell Titer-Glo following lapatinib, crizotinib, TAE684, or ponatinib (1 mM) alone or in com-
bination for 72 hr. Error bars represent mean ± SEM. For biochemical measurement of pStat3, pAKT, PARP, and c-PARP levels, cells were treated with DMSO (D),
lapatinib (L, 2 mM), crizotinib (C, 1 mM), or TAE684 (T, 1 mM), respectively, or cotreated with ponatinib (P, 1 mM) for 24 hr followed by western blot.
(E) SKBR3, EBC-1, or KELLY cells were treated with DMSO or ponatinib (1 mM) for 6 days or lapatinib (2 mM), crizotinib (1 mM), or TAE684 (1 mM) with or without
ponatinib (1 mM) for 40 days. The remaining cells were stained with crystal violet.
(F) The fraction of control for drug-resistant colonies in (E) was analyzed as in (B). Error bars represent mean ± SEM.
All cell staining was performed in 10-cm dishes and entire dishes are shown. See also Figure S5.
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Figure 6. MEK Inhibition Activates Stat3 Signaling in KRAS-Mutant Lung Cancer Cells
(A) A panel ofKRASwild-type ormutant lung and colon cancer cell lines were treated with AZD6244 (5 mM). After 24 hr, cell lysates were subjected to western blot
with the indicated antibodies. b-Actin served as a loading control. H2122 lysates were used as an interblot control.
(B) NTC siRNA or Stat3 siRNA were transfected into cells for 48 hr followed by AZD6244 (5 mM) treatment for 24 hr. T-Stat3, PARP, and c-PARP levels were
detected by western blot. b-Actin served as a loading control. Stat3 knockdown efficiency and cleaved PARP fold changes following Stat3 siRNA in the presence
of AZD6244 were measured by densitometry.
(C) Biochemical measurement of pStat3, T-Stat3, PARP, and c-PARP in indicated cell lines was performed following cotreatment with AZD6244 (5 mM),
PD173074 (2 mM), ruxolitinib (0.5 mM), or ponatinib (1 mM) for 24 hr.
(D) Cell viability of H2009, H2030, or H2122 cells as determined by Cell Titer-Glo following treatment with AZD6244 alone or cotreatment with ponatinib (1 mM) for
72 hr. Error bars represent mean ± SEM.
(legend continued on next page)
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Drug Resistance via Feedback Activation of Stat3binding to regions within 10 kb upstream or downstream of 1,105
genes was significantly increased following erlotinib. When over-
laid with RNA sequencing (RNA-seq) data, we found that expres-
sion of 109 Stat3-regulated genes was changed (Table S1 and
Figure S7B). Notably, 34 of these genes have been implicated
in drug resistance, apoptosis, or tumor progression. Then, in a
cohort of 487 lung adenocarcinoma patients, we found that
high levels of STAT3 itself, as well as the ALPP, ATP2A3,
RARRES1, IL-32, andCFB genes, which were significantly upre-
gulated by Stat3 during erlotinib treatment, are associated with
poor prognosis (Figure 7E; Figures S7C and S7D).
Because lung cancer cell lines with elevated Stat3 expression
demonstrated robust Stat3 feedback activation uponMEK inhib-
itor treatment (Figure 6A), we examined a potential relationship
between Stat3 expression and drug response in patients treated
with EGFR-targeted therapy. We reviewed 103 cases from The
Cancer Genome Atlas (TCGA) lung adenocarcinoma data set
and filtered these down to 12 cases associated with EGFR-tar-
geted therapy (erlotinib or gefitinib). For the EGFR-targeted
drug response analysis, we excluded six patients for whom clin-
ical response information was unavailable or for whom their most
recent treatment was chemotherapy. We then obtained RNA-
seq expression data and analyzed Stat3 expression and drug
response for the remaining cases. Significantly, the three pa-
tients with relatively lower Stat3 expression experienced either
complete response or prolonged tumor-free status following pri-
mary treatment. In contrast, the other three patients with higher
Stat3 expression experienced new tumor development following
a clinical response or progressive disease (Figure 7F). We also
examined the relationship between Stat3 and FGFRs/FRS
expression because cell-line microarray data had revealed that
Stat3, FGFR-2, FGFR-3, and FRS2 expression was highly
co-upregulated by erlotinib (Figure 3A). Indeed, we observed
that the expression correlation between Stat3 and FGFR-2,
FGFR-3, or FRS2 was significantly higher in a targeted therapy
cohort than a chemotherapy-treated cohort (Figure S7E).
Together, these findings suggest that FGFR and Stat3 coexpres-
sion is associated with response to EGFR-targeted therapy and
that a Stat3-responsive gene expression signature may serve
as a marker of poor prognosis in lung adenocarcinoma.
DISCUSSION
Activation of Stat3 has been observed in a variety of human
tumors, including breast cancer, prostate cancer, head and
neck cancer, colon cancer, lung cancer, and multiple myeloma
(Bromberg, 2002). Dysregulated Stat3 signaling has been
strongly implicated in tumorigenesis through effects on cell
growth, angiogenesis, immune system evasion, and prevention
of apoptosis. Although recent studies have revealed activating
Stat3 mutations in hepatocellular adenoma (Pilati et al., 2011)
and large granular lymphocytic leukemia (Koskela et al., 2012),
Stat3 is typically activated nonmutationally in cancer cells
through engagement of cytokine or growth factor receptors.(E) Cells in 10-cm dishes were treated with DMSO or ponatinib (0.5 mM) for 6 da
Remaining cells were stained with crystal violet, and representative entire dishes
(F) The fraction of control for drug-resistant colonies in (E) was analyzed as in Fig
See also Figure S6.Here, we have found that transient Stat3 activation through IL-
6R and FGFR, in response to inhibition of an oncogenic kinase in
‘‘addicted’’ cancer cells, significantly contributes to resistance of
the cell population to drug treatment and consequently limits the
efficacy of such agents. Mechanistic studies clearly demon-
strated that inhibition ofMEK, functioning downstream of various
RTKs (including EGFR, MET, ALK, and HER2) triggers the feed-
back activation of Stat3, indicating a tight link between the MEK
and Stat3 signaling pathways. This general finding was further
extended to KRAS-driven cancers, which also experience onco-
genic signaling via MEK/ERK, suggesting that the coupling of
MEK inhibition and Stat3 activation is broadly conserved across
tumor types and oncogenic contexts, where it appears to simi-
larly affect therapeutic response (Figure 7G). Consistent with
these findings, it has been reported that IL-6 can activate Stat3
in erlotinib-resistant (EGFR T790M) NSCLC cells treated with
an irreversible EGFR inhibitor (Kim et al., 2012) and that MEK
inhibition promotes Stat3 signaling and invasion of melanoma
cells (Vultur et al., 2014).
In addition to the JAK1-Stat3 axis, we found that Stat3 was
activated downstream of FGFR, through PI3K (Figure 7G). On
the basis of previous reports, we speculate that PI3K can posi-
tively affect Stat3 signaling either directly via activation of TEC
tyrosine kinase family members (Guryanova et al., 2011) or indi-
rectly through an autocrine cytokine-mediated mechanism
following NF-kB activation (Hutti et al., 2012). Interestingly,
FGFR-Stat3 signaling appears to play a more significant role in
cell survival and drug resistance in the EGFR mutant xenograft
model, as the erlotinib/ruxolitinib combination was less effective
than erlotinib/ponatinib. In contrast, GDC0973/ruxolitinib signif-
icantly suppressed tumor growth in the KRAS mutant xenograft
model, indicating that JAK-Stat3 signaling contributes to drug
resistance in this model. These findings highlight an element of
complexity associated with the specific mechanisms that drive
the Stat3 feedback loop in cancer cells and suggest a likely
role for cell context-dependent regulation.
Why does this feedback mechanism not fully protect cancer
cells from drug treatment? When considering the relatively slow
kinetics associated with Stat3 feedback activation, and the rela-
tively rapid suppression of oncogenic survival signals observed
following drug treatment, one can imagine that a stochastically
driven ‘‘competition’’ between the rates of engagement of the
apoptotic machinery and the cell-protective feedback signaling
pathway determines the fates of individual cells within a popula-
tion following drug treatment. Thus, we speculate that in the ma-
jority of oncogene-addicted cancer cells in a population that re-
sponds to kinase inhibition, the Stat3 feedback mechanism is
engaged in an ultimately futile attempt by the cell to maintain
viability. However, in a subset of cells, this mechanism is
engaged sufficiently rapidly to prevent an apoptotic outcome.
Although this could reflect a purely stochastic balance between
the rates of activation of the feedback mechanism and decay
of survival signals (which largely favors apoptosis), it is also
possible that a subpopulation of cancer cells is ‘‘primed,’’ priorys or with AZD6244 (5 mM) alone or in combination with ponatinib for 40 days.
are shown.
ure 5B. Error bars represent mean ± SEM.
Cancer Cell 26, 207–221, August 11, 2014 ª2014 Elsevier Inc. 217
0 3 6 9 12 15 18
0
300
600
900
1200
1500 Vehicle
Erlotinib (25 mg/kg)
Ponatinib (30 mg/kg)
Ruxolitinib (25 mg/kg)
Erl/Pona
Erl/Ruxo
Erl/Pona/Ruxo
Time (Days)
Tu
m
or
 V
ol
um
e 
(m
m
3 )
T-EGFR
pEGFR
T-Stat3
pStat3
Ve
hic
le
Er
lot
ini
b
Po
na
tin
ib
1 2 1 2 1 2
Er
l/P
on
a
1 2
T-EGFR
pEGFR
T-Stat3
pStat3
Ve
hic
le
Er
lot
ini
b
Er
l/P
on
a/R
ux
o
Po
na
/R
ux
o
1 2 3 1 2 3 1 2 3 1 2 3
T-ERK
pERK
T-Stat3
pStat3
Ve
hic
le
GD
C0
97
3
GD
C/
Ru
xo
GD
C/
Po
na
GD
C/
Po
na
/R
ux
o
1 2 3 1 2 3 1 2 3 1 2 3 1 2 3
0 3 6 9 12 15
0
300
600
900
1200
1500 Vehicle
GDC0973 (7.5 mg/kg)
Ponatinib (30 mg/kg)
Ruxolitinib (25 mg/kg)
GDC/Pona
GDC/Ruxo
GDC/Pona/Ruxo
Time (Days)
Tu
m
or
 V
ol
um
e 
(m
m
3 )
A B
C D
E F
G
Patients Targeted Drugs
Primary
Response
New 
Tumor
Expression (log2)
Stat3 FGFR2 FGFR3 FRS2
TCGA-64-5778 Erlotinib CR No 11.58993771 7.515816768 8.910843328 5.854983924
TCGA-99-7458 Erlotinib NA No 12.61434553 9.158908692 7.686356572 8.391721832
TCGA-05-4402 Erlotinib CR No 12.97818485 9.34749646 10.82710234 8.640040719
TCGA-86-8075 Gefitinib CR Yes 13.17531485 10.23019894 10.6423615 8.058046554
TCGA-86-8278 Gefitinib CR Yes 13.67542572 8.719360853 6.960713026 7.880629443
TCGA-05-4424 Erlotinib PD Yes 13.81458533 10.13209286 10.79215755 8.689775859
CR: Complete response, PD: Progressive Disease, NA: Not Available. 
RNAseq read counts for Stat3, FGFR2, FGFR3, and FRS2 were converted to expression values 
(log2 - count).
S
tat3
P
ro
ba
bi
lit
y 
(S
ur
vi
va
l)
HR=3.65(2.62-5.1)
logrank P=4.4e-16
low
high
0
0.0
0.2
0.4
0.6
0.8
1.0
50 100 150 200
Time (months)
FGF/FGFR, Stat3
RTKs
RTK/MEK i 
IL-6
FGFRIL-6R
Stat3
JAK1 PI3K
Cell survival genes
p
 mutKRAS
MEK/ERK
Stability
Expression
Figure 7. In Vivo Significance of Stat3 Feedback in the Response to Targeted Ttherapy
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(legend continued on next page)
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Drug Resistance via Feedback Activation of Stat3to treatment, to rapidly engage the Stat3 feedback mechanism
following drug exposure and consequent MEK pathway inhibi-
tion. Although future studies will be required to determine pre-
cisely how Stat3 activation protects cancer cells from apoptosis
following drug treatment, the ChIP-Seq analysis of Stat3 target
genes suggests that several Stat3-regulated genes are associ-
ated with poor prognosis of lung adenocarcinoma patients.
In summary, our findings reveal a seemingly broadly used
cell-protective feedback mechanism that is triggered by MEK
pathway inhibition in a variety of oncogene-addicted cancer
cells. It is especially notable that KRAS-mutant lung cancer cells
that express relatively high levels of Stat3, and actively engage
the Stat3 feedback loop upon MEK inhibition, were significantly
sensitized to the apoptotic effects of MEK inhibition by Stat3
feedback inhibition. Considering that MEK inhibitors are
currently being evaluated for the treatment of KRAS-mutant
lung cancers, these findings reveal a strategy to potentially
improve the efficacy of MEK inhibition by cotreatment with
agents that can disrupt the anticipated Stat3 feedback activation
in these tumors.
EXPERIMENTAL PROCEDURES
Cell Lines and Reagents
RERF-LC-KJ, RERF-LC-OK, VMRC-LCD cells were from the Japan Health
Science Foundation (JHSF and JapaneseCollection of Research Bioresources
Cell Bank). HCC78 and KELLY cells were from Deutsche Sammlung von Mik-
roorganismen und Zellkulturen. EBC-1 cells were from RIKEN. Gp5d cells
were from the European Collection of Cell Cultures. PC-9 cells were provided
by Dr. Kazuto Nishio (National Cancer Center Hospital, Tokyo, Japan). All other
cell lines were from the American Type Culture Collection. Cell line identity is
routinely monitored by SNP-based genotyping at the Genentech cell line
core facility. Cell lines were grown in RPMI 1640 or DMEM/F12 (Gibco) supple-
mented with 10% FBS, 50 U/ml penicillin, 50 U/ml streptomycin, and 2 mM
L-glutamine. Drug treatment was performed in 5% FBS. Lapatinib,
PD173074, ruxolitinib, and AZD6244 (selumetinib) were from LC Laboratories.
Ponatinib, crizotinib, TAE684, TGX-221, and IC-87114were fromSelleckchem.
GDC0941, GDC0464, GDC0973, and erlotinib were synthesized at Genentech.
Immunoblot Analysis
Cells were harvested in NP-40 lysis buffer containing a protease inhibitor
cocktail (Roche). Lysates were then analyzed by western blot. Antibodies
against pStat3, c-PARP, PARP, pERK, ERK, AKT, EGFR, JAK1, JAK2, JAK3,
TYK2, bActin, and GAPDH were from Cell Signaling Technology. Stat3 and
FGFR3 antibodies were from Santa Cruz Biotechnology, pEGFR antibody
was from Abcam, and pAKT antibody was from Invitrogen.
Transcription Factors Pathway Reporter Assay
Each of 45 transcription factor reporters were reverse-transfected into 23 104
PC-9 cells for 48 hr. Cells were then rinsed with PBS and treated with CM from
erlotinib- or DMSO-treated cells for 3 hr, and activities of the 45 transcription(B) Mice bearing HCC4006 tumors were treated with the indicated drugs for 18 d
(C) Mice bearing H2122-derived tumors were treated with GDC-0973 or a comb
pERK, and T-ERK levels were measured in the isolated tumor samples by weste
(D) Seven groups of randomized mice bearing H2122 tumors were treated with the
1,200 mm3. Tumor growth is shown. Error bars represent mean ± SEM.
(E) Kaplan-Meier analysis of the probability of survival as a function of relative exp
probe set was used for the analysis.
(F) Table describing clinical response and Stat3/FGFR2/FGFR3/FRS2 gene expre
Expression values were calculated as log2 from RNA-seq read counts.
(G) Schematic diagram of a widely used Stat3 feedback loop induced by MEK in
See also Figure S7 and Table S1.factors were measured by Cignal Reporter Assays (Qiagen) following theman-
ufacturer’s instructions.
Cell Viability Assays
Cells were seeded at 53 103 cells per well in 96-well plates. The next day, cells
were rinsed and fresh medium was added with DMSO or the various indicated
inhibitors for 72 hr. Cell viability was assayed using a Cell Titer-Glo Lumines-
cent Cell Viability Assay kit (Promega).
siRNAs and Inducible Stat3 Small Hairpin RNA-Expressing Stable
Cell Lines
siRNAs against Stat3, JAK1, JAK2, JAK3, TYK2, and a nontargeting control
were from Dharmacon. Cells were transfected for 48 hr using Lipofectamine
RNAiMAX (Invitrogen), then treated with drugs as indicated. To generate
inducible Stat3 small hairpin RNA (shRNA)-expressing cells, pTRIPZ Inducible
Lentiviral Stat3 shRNAs were purchased from Thermo Scientific. Stat3
shRNAs were transfected into PC-9 cells for 48 hr using Lipofectamine
2000. Cells resistant to puromycin were pooled and red fluorescent protein-
positive clones were generated from fluorescence-activated cell-sorted
subpopulations after 3 days of treatment with doxycycline.
Microarray Analysis
TheAffymetrix Hgu133plus2microarraywas used for gene expression profiles.
Microarray data were normalized using the robust multiple-array average
normalization method. Probes with all samples ‘‘absent’’ (considering a probe
as ‘‘present’’ if its detection p is <0.01 and otherwise as ‘‘absent’’) were
removed from further analysis. To identify differentially expressed genes, we
applied routines implemented in the Bioconductor limma package to fit linear
models to normalized expression values. Variance was corrected by an empir-
ical Bayesian method for better estimation with small sample size (Smyth,
2004). The false discovery rate was limited to less than 0.05, and only probes
with fold changes larger than 1.5-foldwere selected as differentially expressed.
Cytokine Multiplex Assays
PC-9 cells were treated with DMSO or erlotinib (1 mM) for 24 hr. Twenty-three
cytokines from each sample of CMwere analyzed in duplicate according to the
manufacturer’s specifications (Millipore). Standard curves for each cytokine,
using each kit, were generated using the reference cytokine concentrations
supplied by the manufacturer.
Xenograft Studies
All procedures involving animals were reviewed and approved by the Institu-
tional Animal Care and Use Committee at Genentech and carried out in
an Association for the Assessment and Accreditation of Laboratory Animal
Care-accredited facility. For PC-9 and HCC4006 xenografts, 5 3 106 cells
were implanted subcutaneously into the right flanks of Balb/c nude mice
(PC-9) or CB-17 severe combined immunodeficiency mice (HCC4006).
When tumors reached 200 mm3, mice were randomized into seven groups
of seven mice each. Mice were treated with vehicle, erlotinib 25 mg/kg,
ponatinib 30 mg/kg, and ruxolitinib 25 mg/kg, alone or in the indicated combi-
nations for 18 days when tumor sizes in the vehicle control group reached
1,200 mm3. H2122 cells were inoculated subcutaneously into the right flank
area with 1 3 107 cells suspended in Hank’s balanced salt solution/Matrigel.
When tumors reached 300 mm3, mice were randomized into seven groups
of five mice each. Each group was dosed via daily oral gavage with vehicle,ays. Tumor growth is shown. Error bars represent mean ± SEM.
ination of GDC-0973 with ponatinib and ruxolitinib for 24 hr. pStat3, T-Stat3,
rn blot.
various indicated combinations of drugs for 15 days until tumor sizes reached
ression of Stat3 in a cohort of 487 lung adenocarcinoma tumors. 208992_s_at
ssion for six patients treated with EGFR-targeted therapy (erlotinib or gefitinib).
hibition in diverse ‘‘oncogene-addicted’’ cancers.
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Drug Resistance via Feedback Activation of Stat3GDC0973 7.5 mg/kg, ponatinib 30 mg/kg, and ruxolitinib 25 mg/kg alone or in
the indicated combinations for 15 days when tumor sizes in vehicle group
reached 1,200 mm3. Tumor volumes were determined using digital calipers
using the formula (length 3 width 3 width)/2.
Kaplan-Meier Survival Curves
Kaplan-Meier analysis of probability of survival in a 487 lung adenocarcinoma
cohort was performed by the online KM-plotter tool (Gyo¨rffy et al., 2010)
(http://www.kmplot.com).
TCGA Drug Response and Expression Data
TCGA biospecimen and clinical information was obtained from https://
tcga-data.nci.nih.gov/tcgafiles/ftp_auth/distro_ftpusers/anonymous/tumor/
luad/bcr/biotab/clin/.
TCGA Illumina FASTQ sequencing data files were downloaded from
the TCGA website (https://tcga-data.nci.nih.gov/tcga/tcgaDownload.jsp)
and aligned using GSNAP software (Wu and Nacu, 2010). The expression of
each gene was measured as total RNA-seq reads uniquely mapped to the
gene coding regions. Gene expression was then normalized across samples
using the DESeq Bioconductor package (Anders and Huber, 2010). Expres-
sion values shown in the plots are in log2 scale, which was calculated as
log2 (count + 1).
ACCESSION NUMBERS
The Gene Expression Omnibus accession number for the microarray data is
GSE57156, and the European Genome-Phenome Archive accession number
for the RNA and ChIP-seq data is EGAS00001000793.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and one table and can be found with this article online at
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ACKNOWLEDGMENTS
We are grateful to members of the Settleman laboratory for helpful discus-
sions. We thank Tim Wilson, Bob Yauch, David Stokoe, Rich Neve, Nick
Dompe, Genee Lee, and Xiaofen Ye for their comments. We thank Gabriele
Schaefer for providing NR6 and NR6/EGFR del E746_A750 cell lines and the
Genentech gCell facility for providing cancer cell lines and conducting cell
line authentication. All authors are employees of Genentech andmay be share-
holders of Roche Pharmaceuticals.
Received: October 29, 2013
Revised: March 21, 2014
Accepted: May 22, 2014
Published: July 24, 2014
REFERENCES
Anders, S., and Huber,W. (2010). Differential expression analysis for sequence
count data. Genome Biol. 11, R106.
Bao, S., Wu, Q., McLendon, R.E., Hao, Y., Shi, Q., Hjelmeland, A.B., Dewhirst,
M.W., Bigner, D.D., and Rich, J.N. (2006). Glioma stem cells promote radiore-
sistance by preferential activation of the DNA damage response. Nature 444,
756–760.
Bromberg, J. (2002). Stat proteins and oncogenesis. J. Clin. Invest. 109, 1139–
1142.
Bromberg, J.F., Wrzeszczynska, M.H., Devgan, G., Zhao, Y., Pestell, R.G.,
Albanese, C., and Darnell, J.E., Jr. (1999). Stat3 as an oncogene. Cell 98,
295–303.
Chandarlapaty, S., Sawai, A., Scaltriti, M., Rodrik-Outmezguine, V., Grbovic-
Huezo, O., Serra, V., Majumder, P.K., Baselga, J., and Rosen, N. (2011).
AKT inhibition relieves feedback suppression of receptor tyrosine kinase
expression and activity. Cancer Cell 19, 58–71.220 Cancer Cell 26, 207–221, August 11, 2014 ª2014 Elsevier Inc.Daub, H., Specht, K., and Ullrich, A. (2004). Strategies to overcome resistance
to targeted protein kinase inhibitors. Nat. Rev. Drug Discov. 3, 1001–1010.
Duncan, J.S., Whittle, M.C., Nakamura, K., Abell, A.N., Midland, A.A.,
Zawistowski, J.S., Johnson, N.L., Granger, D.A., Jordan, N.V., Darr, D.B.,
et al. (2012). Dynamic reprogramming of the kinome in response to targeted
MEK inhibition in triple-negative breast cancer. Cell 149, 307–321.
Engelman, J.A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J.O.,
Lindeman, N., Gale, C.M., Zhao, X., Christensen, J., et al. (2007). MET ampli-
fication leads to gefitinib resistance in lung cancer by activating ERBB3
signaling. Science 316, 1039–1043.
Guryanova, O.A., Wu, Q., Cheng, L., Lathia, J.D., Huang, Z., Yang, J.,
MacSwords, J., Eyler, C.E., McLendon, R.E., Heddleston, J.M., et al. (2011).
Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic
potential of glioblastoma stem cells by activating STAT3. Cancer Cell 19,
498–511.
Gyo¨rffy, B., Lanczky, A., Eklund, A.C., Denkert, C., Budczies, J., Li, Q., and
Szallasi, Z. (2010). An online survival analysis tool to rapidly assess the effect
of 22,277 genes on breast cancer prognosis using microarray data of 1,809
patients. Breast Cancer Res. Treat. 123, 725–731.
Haber, D.A., Gray, N.S., and Baselga, J. (2011). The evolving war on cancer.
Cell 145, 19–24.
Holohan, C., Van Schaeybroeck, S., Longley, D.B., and Johnston, P.G. (2013).
Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer 13, 714–726.
Huang, Q., Li, F., Liu, X., Li, W., Shi, W., Liu, F.F., O’Sullivan, B., He, Z., Peng,
Y., Tan, A.C., et al. (2011). Caspase 3-mediated stimulation of tumor cell
repopulation during cancer radiotherapy. Nat. Med. 17, 860–866.
Hutti, J.E., Pfefferle, A.D., Russell, S.C., Sircar, M., Perou, C.M., and Baldwin,
A.S. (2012). Oncogenic PI3K mutations lead to NF-kB-dependent cytokine
expression following growth factor deprivation. Cancer Res. 72, 3260–3269.
Kim, S.M., Kwon, O.J., Hong, Y.K., Kim, J.H., Solca, F., Ha, S.J., Soo, R.A.,
Christensen, J.G., Lee, J.H., and Cho, B.C. (2012). Activation of IL-6R/JAK1/
STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors
in non-small cell lung cancer with T790M resistance mutation. Mol. Cancer
Ther. 11, 2254–2264.
Koskela, H.L., Eldfors, S., Ellonen, P., van Adrichem, A.J., Kuusanma¨ki, H.,
Andersson, E.I., Lagstro¨m, S., Clemente, M.J., Olson, T., Jalkanen, S.E.,
et al. (2012). Somatic STAT3mutations in large granular lymphocytic leukemia.
N. Engl. J. Med. 366, 1905–1913.
Krysko, D.V., and Vandenabeele, P. (2008). From regulation of dying cell
engulfment to development of anti-cancer therapy. Cell Death Differ. 15,
29–38.
Lee, H.J., Schaefer, G., Heffron, T.P., Shao, L., Ye, X., Sideris, S., Malek, S.,
Chan, E., Merchant, M., La, H., et al. (2013). Noncovalent wild-type-sparing
inhibitors of EGFR T790M. Cancer Discov 3, 168–181.
Lito, P., Rosen, N., and Solit, D.B. (2013). Tumor adaptation and resistance to
RAF inhibitors. Nat. Med. 19, 1401–1409.
O’Hare, T., Shakespeare, W.C., Zhu, X., Eide, C.A., Rivera, V.M., Wang, F.,
Adrian, L.T., Zhou, T., Huang, W.S., Xu, Q., et al. (2009). AP24534, a pan-
BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I
mutant and overcomes mutation-based resistance. Cancer Cell 16, 401–412.
Pilati, C., Amessou,M., Bihl, M.P., Balabaud, C., Nhieu, J.T., Paradis, V., Nault,
J.C., Izard, T., Bioulac-Sage, P., Couchy, G., et al. (2011). Somatic mutations
activating STAT3 in human inflammatory hepatocellular adenomas. J. Exp.
Med. 208, 1359–1366.
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D.,
Beijersbergen, R.L., Bardelli, A., and Bernards, R. (2012). Unresponsiveness of
colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.
Nature 483, 100–103.
Roesch, A., Fukunaga-Kalabis, M., Schmidt, E.C., Zabierowski, S.E., Brafford,
P.A., Vultur, A., Basu, D., Gimotty, P., Vogt, T., and Herlyn, M. (2010). A tempo-
rarily distinct subpopulation of slow-cycling melanoma cells is required for
continuous tumor growth. Cell 141, 583–594.
Sharma, S.V., and Settleman, J. (2007). Oncogene addiction: setting the stage
for molecularly targeted cancer therapy. Genes Dev. 21, 3214–3231.
Cancer Cell
Drug Resistance via Feedback Activation of Stat3Sharma, S.V., Bell, D.W., Settleman, J., and Haber, D.A. (2007). Epidermal
growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 7, 169–181.
Sharma, S.V., Lee, D.Y., Li, B., Quinlan, M.P., Takahashi, F., Maheswaran, S.,
McDermott, U., Azizian, N., Zou, L., Fischbach, M.A., et al. (2010). A chro-
matin-mediated reversible drug-tolerant state in cancer cell subpopulations.
Cell 141, 69–80.
Shuai, K., Horvath, C.M., Huang, L.H., Qureshi, S.A., Cowburn, D., and Darnell,
J.E., Jr. (1994). Interferon activation of the transcription factor Stat91 involves
dimerization through SH2-phosphotyrosyl peptide interactions. Cell 76,
821–828.
Singh, A., and Settleman, J. (2010). EMT, cancer stem cells and drug resis-
tance: an emerging axis of evil in the war on cancer. Oncogene 29, 4741–4751.
Smyth, G.K. (2004). Linear models and empirical bayes methods for assessing
differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol.
3, e3.
Sos, M.L., Koker, M., Weir, B.A., Heynck, S., Rabinovsky, R., Zander, T.,
Seeger, J.M., Weiss, J., Fischer, F., Frommolt, P., et al. (2009). PTEN loss
contributes to erlotinib resistance in EGFR-mutant lung cancer by activation
of Akt and EGFR. Cancer Res. 69, 3256–3261.
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z.R., Du, J.,
Davis, A., Mongare, M.M., Gould, J., Frederick, D.T., et al. (2012). Tumour
micro-environment elicits innate resistance to RAF inhibitors through HGF
secretion. Nature 487, 500–504.
Vultur, A., Villanueva, J., Krepler, C., Rajan, G., Chen, Q., Xiao, M., Li, L.,
Gimotty, P.A., Wilson, M., Hayden, J., et al. (2014). MEK inhibition affectsSTAT3 signaling and invasion in human melanoma cell lines. Oncogene 33,
1850–1861.
Wang, S.E., Narasanna, A., Perez-Torres, M., Xiang, B., Wu, F.Y., Yang, S.,
Carpenter, G., Gazdar, A.F., Muthuswamy, S.K., and Arteaga, C.L. (2006).
HER2 kinase domain mutation results in constitutive phosphorylation and
activation of HER2 and EGFR and resistance to EGFR tyrosine kinase
inhibitors. Cancer Cell 10, 25–38.
Wang, X., Crowe, P.J., Goldstein, D., and Yang, J.L. (2012). STAT3 inhibition, a
novel approach to enhancing targeted therapy in human cancers (review). Int.
J. Oncol. 41, 1181–1191.
Wen, Z., Zhong, Z., and Darnell, J.E., Jr. (1995). Maximal activation of tran-
scription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation.
Cell 82, 241–250.
Wilson, T.R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., Peng, J.,
Lin, E., Wang, Y., Sosman, J., et al. (2012). Widespread potential for growth-
factor-driven resistance to anticancer kinase inhibitors. Nature 487, 505–509.
Wu, T.D., and Nacu, S. (2010). Fast and SNP-tolerant detection of complex
variants and splicing in short reads. Bioinformatics 26, 873–881.
Yonesaka, K., Zejnullahu, K., Lindeman, N., Homes, A.J., Jackman, D.M.,
Zhao, F., Rogers, A.M., Johnson, B.E., and Ja¨nne, P.A. (2008). Autocrine
production of amphiregulin predicts sensitivity to both gefitinib and cetuximab
in EGFR wild-type cancers. Clin. Cancer Res. 14, 6963–6973.
Yu, H., Pardoll, D., and Jove, R. (2009). STATs in cancer inflammation and
immunity: a leading role for STAT3. Nat. Rev. Cancer 9, 798–809.Cancer Cell 26, 207–221, August 11, 2014 ª2014 Elsevier Inc. 221
